CompletedNot Applicable

Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

United States1,000 participantsStarted 2008-06

Plain-language summary

Validate that circulating cell free fetal nucleic acid can be used to identify a direct marker for fetal aneuploidy, particularly fetal Down Syndrome (DS), that is better than surrogate markers.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject is female * Subject is pregnant * Subject is high risk aneuploid patient undergoing genetic counseling, unltrasound screening, amniocentesis and/or CVS procedure * Subject is willing to provide blood specimen Exclusion Criteria: * Subject is not pregnant * Subject is not willing to provide blood specimen * Subject is not haveing aneuploid screening

What they're measuring

Compare investigational assay results for Down Syndrome to standard of care results.

Timeframe: 3 months

Trial details

NCT IDNCT00770458

SponsorSequenom, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2009-10

View on ClinicalTrials.gov More Down Syndrome (Trisomy 21) trials